Zevra Therapeutics, Inc. (NASDAQ: KMPH)
Quick take: Management converted FDA approval into commercial revenue (MIPLYFFA), monetized a transferable PRV for a one‑time $148.3M net gain that materially improved cash and profit for the quarter, but wrote down an acquired product intangible (OLPRUVA) ...